Provenance Record

All three source URLs are accessible. Intellia press release on hold lift (Source 1): Confirmed FDA hold lift, MAGNITUDE Phase 3, nex-z for ATTR-CM, mitigation measures (enhanced liver monitoring, steroid guidance, ejection fraction <25% exclusion), ~1,200 patient enrollment target, CEO John Leonard quote verified verbatim. Intellia initial disclosure (Source 2): Confirmed September 30, 2025 dosing, Grade 4 liver transaminase elevations, increased bilirubin, October 24 hospitalization, voluntary pause of MAGNITUDE and MAGNITUDE-2, 450+ patients dosed in MAGNITUDE, 47 enrolled in MAGNITUDE-2. GlobeNewsWire (Source 3): Republication of Intellia March 2, 2026 press release. Does NOT contain patient death date, death event, comorbidity mentions, or treating physician statements.

CRITICAL: The article claims 'The patient subsequently died on November 5, 2025' hyperlinked to GlobeNewsWire (Source 3) and adds 'with the treating physician noting complicating comorbidities as a contributing factor.' Neither the death, the date November 5, nor the comorbidity/physician statement appear anywhere in the GlobeNewsWire source. This is an unsourced claim in a sensitive medical context. Additionally, MAGNITUDE-2 enrollment: article says 47 patients (from October 2025 Source 2), but March 2026 Source 3 says 'approximately 60 patients.'

REQUEST_CHANGES. The article is well-structured and covers an important CRISPR medicine development. However, the most sensitive claim — that a trial participant died on a specific date with complicating comorbidities — is attributed to a source that does not contain this information. This must be corrected by either finding and citing the actual source for the death claim, or removing the unsourced details.

All three cited sources fetched and reviewed in full (2026-03-17). Source 1 (ir.intelliatx.com — FDA lift press release, March 2, 2026): Confirms FDA lifted the MAGNITUDE clinical hold, lists safety measures (enhanced liver monitoring, steroid guidance, exclusion criteria including EF <25%), confirms MAGNITUDE-2 hold resolved in January 2026, CEO John Leonard quote verified. Does NOT mention patient death, November 5 date, comorbidities, or 450+ patient count. Source 2 (ir.intelliatx.com — MAGNITUDE update, October 27, 2025): Confirms patient dosed September 30, 2025, Grade 4 liver transaminase elevations reported October 24, voluntary enrollment pause by Intellia, 47 patients in MAGNITUDE-2, over 450 patients dosed across both trials combined. Does NOT mention patient death, hospitalization date of October 24 (only adverse event report date), FDA-imposed hold, or comorbidities. Source 3 (GlobeNewsWire): Duplicate of Source 1. Does NOT mention patient death, November 5 date, or comorbidities.

CRITICAL: Multiple unsourced claims. (1) Patient death on November 5, 2025 is not substantiated by any cited source. (2) 'Complicating comorbidities as a contributing factor' attributed to the treating physician appears in no cited source. (3) The 450+ patient figure is misattributed to MAGNITUDE alone when the source says it applies across both trials combined. (4) The FDA hold date of October 29, 2025 and characterization as FDA-imposed rather than voluntary are not supported by the cited October 27 press release. (5) October 24 is cited as the hospitalization date but the source only says the adverse event was reported on that date.

The article is well-structured and covers a genuinely important topic, but it contains multiple factual claims that cannot be traced to any of the three cited sources. Per editorial policy, every claim must trace to a cited source. The article must either add sources that substantiate the death/comorbidity claims or remove those claims entirely, and correct the misattributed patient count and FDA hold characterization.